Indivior PLC to Post Q2 2024 Earnings of $0.46 Per Share, Northland Capmk Forecasts (NASDAQ:INDV)

Indivior PLC (NASDAQ:INDV) – Analysts at Northland Capmk decreased their Q2 2024 earnings estimates for shares of Indivior in a research note issued on Thursday, April 25th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings of $0.46 per share for the quarter, down from their previous forecast of $0.47. The consensus estimate for Indivior’s current full-year earnings is $2.03 per share. Northland Capmk also issued estimates for Indivior’s Q3 2024 earnings at $0.53 EPS and Q4 2024 earnings at $0.58 EPS.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Thursday, February 22nd. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.15. Indivior had a return on equity of 700.00% and a net margin of 0.44%. The business had revenue of $293.00 million for the quarter, compared to the consensus estimate of $260.00 million.

Separately, Craig Hallum assumed coverage on Indivior in a report on Wednesday, April 3rd. They issued a “buy” rating and a $37.00 price target for the company.

Indivior Price Performance

Shares of INDV stock opened at $17.58 on Monday. The stock’s fifty day moving average price is $20.49 and its 200 day moving average price is $18.29. Indivior has a 1-year low of $14.38 and a 1-year high of $26.50. The company has a market cap of $2.42 billion, a price-to-earnings ratio of 1,758.00 and a beta of 0.46.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Chilton Investment Co. Inc. purchased a new stake in shares of Indivior during the fourth quarter valued at $263,000. ADAR1 Capital Management LLC acquired a new stake in Indivior during the 4th quarter worth about $368,000. Cannon Global Investment Management LLC purchased a new stake in Indivior during the 1st quarter valued at about $563,000. Campbell & CO Investment Adviser LLC acquired a new position in shares of Indivior in the third quarter valued at about $801,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Indivior by 15.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,596 shares of the company’s stock valued at $860,000 after purchasing an additional 5,365 shares during the period. Institutional investors and hedge funds own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.